|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
MediGene_AG_(2018)
AstraZeneca's_rights_to_Lenvatinib_(2014)
|
|
gptkbp:advertising
|
gptkb:Ms._Sayaka_Nishida
gptkb:Ms._Emi_Kobayashi
gptkb:Mr._Hiroshi_Taniguchi
gptkb:Ms._Aiko_Tanaka
gptkb:Mr._Yuji_Takeda
gptkb:Ms._Akiko_Saito
gptkb:Ms._Yuki_Tanaka
Mr. Ryoichi Takahashi
Mr._Satoshi_Watanabe
|
|
gptkbp:budget
|
published
|
|
gptkbp:CEO
|
Haruo Naito
|
|
gptkbp:clinicalTrials
|
gptkb:Mr._Tetsuya_Yamashita
gptkb:Dr._Akira_Matsumoto
ongoing
Phase II
cancer
neurodegenerative diseases
Phase III
pain management
Phase I
|
|
gptkbp:collaborations
|
gptkb:Harvard_Medical_School
gptkb:Yale_University
gptkb:University_of_Tokyo
|
|
gptkbp:customerService
|
gptkb:Mr._Taro_Yamada
|
|
gptkbp:employees
|
over 10,000
|
|
gptkbp:focus
|
metabolic disorders
neurology
oncology
|
|
gptkbp:founded
|
1941
|
|
gptkbp:founder
|
gptkb:Toichi_Eisai
|
|
gptkbp:headCoach
|
gptkb:Ms._Haruka_Sato
gptkb:Dr._Hiroshi_Saito
gptkb:Dr._Kenji_Takeda
gptkb:Mr._Kenta_Yoshida
|
|
gptkbp:headquarters
|
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eisai Co., Ltd.
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:market
|
global
|
|
gptkbp:partnerships
|
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Daiichi_Sankyo
|
|
gptkbp:patentCitation
|
numerous
|
|
gptkbp:philanthropy
|
Eisai_Co.,_Ltd._Foundation
|
|
gptkbp:products
|
medications
|
|
gptkbp:regulatoryCompliance
|
gptkb:Ms._Yuki_Matsumoto
gptkb:Ms._Rina_Suzuki
gptkb:Ms._Yoko_Matsuda
|
|
gptkbp:research
|
gptkb:Dr._Takashi_Yamamoto
gptkb:Dr._Masato_Inoue
Alzheimer's disease
cancer treatments
epilepsy
|
|
gptkbp:revenue
|
$4.5 billion (2021)
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
4523
|
|
gptkbp:subsidiary
|
gptkb:Eisai_Europe_Ltd.
gptkb:Eisai_Inc.
|
|
gptkbp:supplyChain
|
gptkb:Mr._Junichi_Nakamura
gptkb:Mr._Kenjiro_Takahashi
|
|
gptkbp:tactics
|
gptkb:Mr._Masahiro_Fujimoto
|
|
gptkbp:website
|
www.eisai.com
|